NEJM: Clinical Phase 1 of Novavax's new crown candidate vaccine shows good safety and reactive originality.

In a study published September 2 in the New England Journal of Medicine, the results of a phase 1 clinical study, Phase 1 clinical trial of Novavax's COVID-19 vaccine NVX-CoV2373, showed: The vaccine candidate, used in healthy adults aged 18-59, showed reassuring safety and reactogenicity characteristics, and induced neutral antibody titrations up to four times as high as in patients with recovery-period COVID-19.
Phase 1 Trial Results Summary: Safety: NVX-CoV2373 Good tolerance, reactive primary events are usually mild; Reactive primary: All subjects in the 5 sg group produced anti-prickly protein IgG antibodies after a single vaccination, many of whom also produced neutral antibody responses against wild viruses;1 00% of the subjects had a wild viral negation and antibody response after the second dose, and the results showed that matrix-M adulators significantly enhanced the subject's antibody response, with a dose of NVX CoV of 5 μg. 2373 is equivalent to the average geometric titration (GMT) of the meso-antibody triggered by NVX CoV2373 at a dose of 25 μg, with a peak of more than 3300, compared to the response of patients with COVID-19 recovery period. The anti-prickline protein IgG antibody and viral neutral response were better, and the cellular immune response measured in a sub-group of subjects proved that induced antigen-specific multifunction CD44-positive T-cell response had strong Th1 esoteric bias.
different doses of NVX-CoV2373 vaccine, placebo subjects and rehab patients with mesothropic antibody titration (Human Convalescent Serum, rehabilitation patient serum; Asymptomatic, asymptomatic patients; Patients with symptoms; Hospitalized, hospitalized; Photo: Reference: Reference s.2) NVX-CoV2373 is a sequence of new coronavirus genes (Gen Bank, MN908947; nucleotides 21563-25384) modified candidate vaccines.
it is produced using Novavax's recombinant nanoparticle technology to produce antigens for the new coronavirus pyrethroid protein.
It also contains Novavax's proprietary saponin-based Matrix-M advent, which enhances the immune response and stimulates high levels of mesothetic antibody production by stimulating antigen delivery cells to enter the injection site and enhancing antigen delivery in the local lymph nodes.
in preclinical trials, NVX-CoV2373 demonstrated that it can block the binding of prickly proteins to viral targeted receptors, which is a key to effective protection for vaccines.
NVX-CoV2373 is currently in phase 2 clinical trials, and Phase 2 of the Phase 1/2 clinical trial to assess the safety and immunogenicity of NVX-CoV2373 began in august in the United States and Australia, expanding the phase 1 age range to include people aged 60-84 in the trial population.
: s1. Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine NVX-CoV2373 was generally well-well-of-well-of-the-long and elicited robust antibody responses numerically to that seen in human convalescent sera. Retrieved September 2, 2020, from .2, Cheryl Keech, et al., (2020). Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med, DOI: 10.1056/NEJMoa2026920.